Biotech

All Articles

AN 2 one-halfs census, ceases period 3 trial after data dissatisfy

.AN2 Rehabs is actually reviewing its service in action to uninspired midphase records, promising to...

Merck pays out $700M for bispecific, snooping autoimmune opening and possibility to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand upfront to test Amgen in a blood cancer cells market. The ...

Gilead pays for J&ampJ $320M to exit licensing bargain for seladelpar

.With Gilead Sciences almost an FDA choice for its own liver disease medicine seladelpar, the compan...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks may see the firms setting up outdoors tents at basecamp behind ...

Entero laying off workers, abandoning workplace and also stopping briefly R&ampD

.Cushion Liquidators has turned Entero Rehabs white as a sheet. The financial institution bought Ent...

Exelixis loses ADC after determining it is actually no match for Tivdak

.Exelixis is actually losing hope on its own cells factor (TF)- targeting antibody-drug conjugate af...

Relay dislikes SHP2 prevention after Genentech leaves

.3 weeks after Roche's Genentech unit walked away from an SHP2 inhibitor contract, Relay Therapy has...

Stoke's Dravet syndrome med discharged of partial medical hold

.Stoke Therapeutics' Dravet disorder medication has been actually without a predisposed grip, cleari...

Fierce Biotech's Gabrielle Masson presents Ferocious 15 at NYSE

.Tough Biotech Associate Editor Gabrielle Masson offered the 2024 training class of Intense 15 champ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has axed its once-monthly twin GLP-1/ GIP receptor agonist, ending (PDF) development o...